HUNS 001
Alternative Names: Autologous mesenchymal stem cell -RAINBOW; HUNS-001; HUNS001-01Latest Information Update: 04 Mar 2025
Price :
$50 *
At a glance
- Originator Hokkaido University; RAINBOW
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cerebral infarction
Most Recent Events
- 09 Jan 2025 RAINBOW has patents pending for 'Platelet lysate derived from autologous platelets' in USA
- 03 Jan 2025 Phase-II clinical trials in Cerebral infarction in USA (Intracerebral) prior to January 2025 (RAINBOW pipeline, January 2025)
- 03 Jan 2025 RAINBOW anticipates to receive conditional marketing approval from regulatory body for Cerebral infarction in Japan in 2030 (RAINBOW pipeline, January 2025)